11 September 2026
11 September 2026
The lens will launch in select European countries in 2026, with broader rollout planned for 2027 and 2028.
The site will produce bioprocess equipment and consumables used in developing biologics and vaccines.
The FDA's decision follows a clinical assessment of the Emboliner, including the PROTECT H2H IDE study.
In the trial, dabogratinib’s safety profile was evaluated in 60mg and 50mg once-daily cohorts, each with 22 participants.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
